tiprankstipranks
In this article:
Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Immunic (IMUX), OncoSec Medical (ONCS)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunic (IMUXResearch Report) and OncoSec Medical (ONCSResearch Report) with bullish sentiments.

Immunic (IMUX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Immunic today and set a price target of $61.00. The company’s shares closed last Wednesday at $8.85, close to its 52-week low of $6.96.

According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -3.8% and a 33.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunic with a $49.75 average price target, representing a 462.1% upside. In a report issued on December 14, Leerink Partners also maintained a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

OncoSec Medical (ONCS)

In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on OncoSec Medical, with a price target of $10.00. The company’s shares closed last Wednesday at $1.22, close to its 52-week low of $1.12.

According to TipRanks.com, Pohlman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.0% and a 31.6% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Checkmate Pharmaceuticals, Mersana Therapeutics, and CytomX Therapeutics.

OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IMUX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed